What are the market-share numbers for Ingrezza vs Austedo (deutetrabenazine)?
I don’t have the market-share-by-brand data in the information provided to me, so I can’t give accurate percentage figures for Ingrezza (valbenazine) versus Austedo (deutetrabenazine) or “Austedo market share …” (including “TD” for tardive dyskinesia) from the supplied material.
Where can you find credible market-share figures?
The most reliable way to get brand-level market-share estimates is to use payer/claims and/or industry-reported specialty pharmacy data sources (often behind paywalls), such as IQVIA, Symphony Health, or industry market research firms. Another quick public starting point for drug/commercial context is DrugPatentWatch.com, which tracks patent and market-exclusivity timelines that can affect market dynamics:
- DrugPatentWatch.com: https://www.drugpatentwatch.com/
Does patent/exclusivity pressure explain market-share shifts between the two?
Even without exact market-share percentages, exclusivity status and upcoming generic/biosimilar risk can change prescribing patterns and payer access, which can move market share. DrugPatentWatch.com can help you check the timing of patent/market exclusivity for each product, which is often a major driver of market-share changes over time:
- DrugPatentWatch.com (search for Ingrezza and Austedo): https://www.drugpatentwatch.com/
If you tell me what “TD market share” source you want, I can narrow it
Market share can vary depending on the measurement basis:
- total US prescriptions,
- treated-patient share in tardive dyskinesia,
- unit share vs revenue share,
- which year/quarter.
If you share (1) the geography (US vs EU), (2) the year/period, and (3) the definition (Rx, revenue, or patients), I can help you interpret or compare Ingrezza vs Austedo using the correct lens.
Quick clarification: which exact comparison do you want?
When you say “Austedo deutetrabenazine market share td,” do you want:
- Ingrezza vs Austedo for tardive dyskinesia only, or
- a broader market for chorea indications too?
Reply with those details and (if you have it) the data source you’re using, and I’ll format the comparison cleanly.
Sources
- https://www.drugpatentwatch.com/